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Abstract
Background: Cerebellar ataxia (CA) is a frequent and often disabling condition that impairs motor functioning and impacts
on quality of life (QoL). No medication has yet been proven effective for the symptomatic or even causative treatment of
hereditary or non-hereditary, non-acquired CA. So far, the only treatment recommendation is physiotherapy. Therefore, new
therapeutic options are needed. Based on three observational studies, the primary objective of the acetyl-DL-leucine on
ataxia (ALCAT) trial is to examine the efficacy and tolerability of a symptomatic therapy with acetyl-DL-leucine compared to
placebo on motor function measured by the Scale for the Assessment and Rating of Ataxia (SARA) in patients with CA.
Methods/Design: An investigator-initiated, multicenter, European, randomized, double-blind, placebo-controlled, 2-
treatment 2-period crossover phase III trial will be carried out. In total, 108 adult patients who meet the clinical criteria
of CA of different etiologies (hereditary or non-hereditary, non-acquired) presenting with a SARA total score of at least 3
points will be randomly assigned in a 1:1 ratio to one of two different treatment sequences, either acetyl-DL-leucine (up
to 5 g per day) followed by placebo or vice versa. Each sequence consists of two 6-week treatment periods, separated by
a 4-week wash-out period. A follow-up examination is scheduled 4 weeks after the end of treatment. The primary efficacy
outcome is the absolute change in the SARA total score. Secondary objectives are to demonstrate that acetyl-DL-leucine
is effective in improving (1) motor function measured by the Spinocerebellar Ataxia Functional Index (SCAFI) and SARA
subscore items and (2) QoL (EuroQoL 5 dimensions and 5 level version, EQ-5D-5 L), depression (Beck Depression Inventory,
BDI-II) and fatigue (Fatigue Severity Score, FSS). Furthermore, the incidence of adverse events will be investigated.
Discussion: The results of this trial will inform whether symptomatic treatment with the modified amino-acid acetyl-DL-
leucine is a worthy candidate for a new drug therapy to relieve ataxia symptoms and to improve patient care. If superiority
of the experimental drug to placebo can be established it will also be re-purposing of an agent that has been previously
used for the symptomatic treatment of dizziness.
(Continued on next page)
* Correspondence: katharina.feil@med.uni-muenchen.de
1Department of Neurology with Friedrich-Baur-Institute, University Hospital,
Munich, Germany
2German Center for Vertigo and Balance Disorders (DSGZ), University
Hospital, Munich, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Feil et al. BMC Neurology  (2017) 17:7 
DOI 10.1186/s12883-016-0786-x
(Continued from previous page)
Trial registration: The trial was prospectively registered at www.clinicaltrialsregister.eu (EudraCT no. 2015–000460–34) and
at https://www.germanctr.de (DRKS-ID: DRKS00009733).
Keywords: Cerebellar ataxia, Amino acids, Acetyl-DL-leucine, Symptomatic therapy, Randomized controlled trial, Crossover
design, Ataxia rating scales, Patient questionnaires, Quality of life
JEL classification: 30.040 Ataxia, 20.060 Clinical trial, 10.070 Movement disorders, 30.260 Neurodegeneration, 20.140
Qualitative research
Background
Cerebellar ataxia (CA) is a frequent and often disabling
syndrome which can severely impair motor functioning
and quality of life (QoL) [1]. CAs are most often caused
by neurodegenerative disorders of the cerebellum
which are either hereditary or non-hereditary (spor-
adic); all in all, about 50% of the cases are sporadic.
Studies suggest that the overall prevalence of CA in
Europe is similar to that in Japan and may approach
20:100,000, i.e., 15,000 patients in Germany (www.atax-
ie.de) [2]. Due to the various etiologies and different
courses of the diseases, there are no robust epidemio-
logical data on CA-related mortality.
The leading clinical symptoms of CA are disturbances
of stance or gait (>85%) with recurrent falls, limb ataxia
with severe functional impairment of arm and hand
movements, dysarthrophonia with impaired oral com-
munication abilities, and ocular motor disturbances with
impaired vision [1]. Further, most types of CA are pro-
gressive and therefore become more disabling in the
course of the disease, severely impairing QoL and func-
tioning [1]. In addition to functional impairment, CA
also affects cognitive and psychosocial abilities and limits
the ability to perform tasks of daily life. It is thus a
severely disabling condition, progressively restricting
autonomy and social participation. The care that is
required is frequently provided by the family, thus fur-
ther increasing the socioeconomic burden of disease [3].
Major cost components relevant for patients with CA
are informal care, early retirement because of permanent
disability, drugs, orthopedic devices, and rehabilitation.
As the disease progresses, quality of life decreases and
utilization of health resources increases [4].
No medication has yet been proven effective for the
symptomatic or even causative treatment of degenerative
CA [5]. Beneficial effects of Varenicline and Riluzole have
been reported [6–8]. However, according to a consensus
paper on management of degenerative CA, these findings
need to be further confirmed in further placebo-
controlled trials, in particular long-term and disease-
specific studies [8, 9]. To date, the only treatment
recommendation for CA is physiotherapy [10] and new
therapeutic options are needed.
Acetyl-DL-leucine
Acetyl-DL-leucine (Tanganil; Pierre Fabre, Castres,
France) is an acetylated derivative of a natural essential
amino acid. Although it has been used for more than
50 years, mainly in France for the symptomatic treat-
ment of acute vertigo and dizziness and improvement of
central vestibular compensation [11], the therapeutic
mode of action of acetyl-DL-leucine has so far not been
very well examined. It may act due to its direct effect on
neurons, as was shown in the vestibular nuclei [11]. In
vitro studies in guinea pigs demonstrated that acetyl-
DL-leucine acts mainly on abnormally hyperpolarized
and/or depolarized vestibular neurons by normalizing
the membrane potential and has only a minor effect on
the membrane potential of vestibular neurons during
normal resting potential [12]. In unilateral neurotomy
and labyrinthectomy, the agent was described to
normalize the vestibular asymmetry with showing an ef-
fect seen only in the subgroup of patients with residual
vestibular function [11]. Due to the phylogenetical and
electrophysiological similarities and close interactions
between vestibular and deep cerebellar neurons [13], we
had hypothesized that there may also be a positive effect
on ataxic symptoms in cerebellar disorders. In an animal
model on acute unilateral vestibulopathy, it was found
that acetyl-DL-leucine improves compensation of pos-
tural symptoms most likely by activation of the vestibu-
locerebellum, since there was a significant increase of
the regional cerebral metabolic rate for glucose in the
paraflocculus/flocculus [14]. On cellular levels, it was
demonstrated that acetyl-DL-leucine restores the mem-
brane potential of hyperpolarized/depolarized vestibular
neurons after unilateral labyrinthectomy in guinea pigs
[12]. This mechanism may be mediated by its direct in-
teractions with membrane phospholipids such as phos-
phatidylinositol 4,5-bisphosphate, which influences ion
channel activity [15]. Thereby, acetyl-DL-leucine can
stabilize the membrane potential. The input from cere-
bellar Purkinje cells and mossy/climbing fiber collat-
erals controls the action potential of the vestibular and
the cerebellar nuclei [16], which in turn project to the
brainstem, thalamus and spinal cord [13]. Therefore,
acetyl-DL-leucine may act through afferent and efferent
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projections on upstream and downstream structures,
thus influencing movement control.
Trial rationale
In a first case series on 13 patients with different types of
hereditary and non-hereditary non-acquired CA, we re-
ported positive effects of acetyl-DL-leucine (5 g per day for
one week) on the motor function measured by the Scale for
the Assessment and Rating of Ataxia (SARA) and the Spi-
nocerebellar Ataxia Functional Index (SCAFI) [17]. The
agent was well tolerated [17]. Mean total SARA decreased
from 16.1 ± 7.1 (mean ± SD) at baseline to 12.8 ± 6.8 after
one week on medication (p = 0.002), and patients showed
better performance in the SCAFI consisting of the 8-m-
walking-time (8 MW), 9-Hole-Peg-Test of the dominant
hand (9HPTD) and the PATA rate task (timed speech task
where the patient is asked to repeat “PATA” as quickly and
distinctly as possible for 10 s two times). Preliminary FDG-
PET-data in a case series of 18 patients suffering from de-
generative CA with different etiologies showed central
compensation processes in the group of responders mainly
in the medulla (vestibular nuclei), midbrain (vestibular inte-
gration centers), thalami, basal ganglia and insular regions
rather than neurons in the cerebellum, the primary site of
dysfunction in CA syndromes [18]. In gait analysis, acetyl-
DL-leucine improved the coefficient of variation of stride
time in 14 out of 18 cerebellar patients. Acetyl-DL-leucine
showed a reduction of gait variability during slow walking
[19], whereas aminopyridines have been shown to improve
gait variability mainly during fast walking [20, 21]. Subject-
ive ambulatory gait scores and the SARA score also im-
proved under treatment [19]. Further, in a case series on 12
patients with Niemann-Pick type C, a lysosomal storage
disorder, there was also a significant improvement of symp-
toms of ataxia [22]. On the other side, the use of the liquid
formula of acetyl-DL-leucine 5 g once daily for 7 days in 10
patients with degenerative CA failed to confirm a treatment
benefit of the drug in combination with a short-term phy-
sio— and occupational therapy, although 7 out of 10 pa-
tients reported subjective improvement [23]. However, all
these case studies provide limited evidence and have con-
siderable methodological limitations. Efficacy outcomes
were assessed unblinded, rendering objective evaluation of
treatment response difficult. Large-scale double-blind ran-
domized controlled trials are highly warranted. Based on
these results, we designed the prospective ALCAT trial (Ef-
fects of Acetyl-DL-Leucine on Cerebellar ATaxia) to inves-
tigate the efficacy and safety of acetyl-DL-leucine with the
aim of demonstrating superiority over placebo.
Methods/Design
Trial design and setting
The ALCAT trial is an investigator-initiated, multicenter,
randomized, double-blind, placebo-controlled, 2-treatment
2-period crossover phase III trial. The study was initiated at
the Department of Neurology and the German Center for
Vertigo and Balance Disorders (University of Munich) and
the Friedrich-Baur-Institute, and has been subsequently ex-
tended to other study sites located in Germany (University
of Tuebingen, University of Essen, and DZNE Bonn),
Austria (Innsbruck) and will be expanded to the
Netherlands (Nijmegen). The study has been approved
by the responsible ethics committees in Germany
(project number 248–15 fed) as well as the ethics
committee in Austria (project number AN2015–0252
355/2.1) and has been submitted to the ethics com-
mittee in the Netherlands. Furthermore, the study has
been approved by the legal medical regulatory author-
ities (Federal Institute for Drugs and Medical Devices,
in German: Bundesinstitut für Arzneimittelsicherheit
und Medizinprodukte - BfArM in Germany, Austrian
Agency for Health and Food Safety Ltd. AGES, in German:
Österreichische Agentur für Gesundheit und Ernährungs-
sicherheit GmbH in Austria, Central Committee on Re-
search Involving Human Subjects, in Dutch: Centrale
Commissie Mensgebonden Onderzoek – CCMO in the
Netherlands). The first patient was randomized on January
25, 2016. The ALCAT trial is conducted in accordance
with the International Conference for Harmonisation (of
Technical Requirements for Pharmaceuticals for Human
Use) - Good Clinical Practice Guideline (ICH-GCP) and
the Declaration of Helsinki. The trial has been prospect-
ively registered at www.clinicaltrialsregister.eu (EudraCT
no. 2015–000460–34) and https://www.germanctr.de (DR
KS-ID: DRKS00009733) on January 15, 2016. Patient insur-
ance for the study has been arranged (policy number for
Germany 39 130537 03026, for Austria 07208763–1, for
Netherlands 081 50474–14005).
Patient population and eligibility criteria
Patients are screened for eligibility according to the in-
clusion and exclusion criteria. To be eligible for the
study, patients aged 18 years or older must present with
the clinical symptom of ataxia (hereditary or non-
hereditary, non-acquired CA) with at least 3 points in
the SARA total score and be able to understand and fol-
low instructions and to give informed consent. All rele-
vant medical and non-medical conditions should be
taken into consideration when deciding whether this
protocol is suitable for a particular subject. The ex-
clusion criteria were chosen according to available
data on acetyl-DL-leucine from the French Agence
nationale de sécurité du médicament et des produits
de santé (http://agence-prd.ansm.sante.fr/php/ecodex/
notice/N0126720.htm, accessed on 24.04.2015, dated
on 20.02.2007) and included, in particular, hypersensi-
tivity to the agent. For a detailed description of inclu-
sion and exclusion criteria see Table 1.
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Recruitment and patient involvement
Patients will be recruited via personal correspondence
and by routine care appointments at specialized tertiary
referral centres (Neurological departments of University
hospitals). In Germany, we also cooperate with the
Deutsche Heredo-Ataxie Gesellschaft e.V. (DHAG), a
self-help group of ataxia patients. All eligible CA
patients who agree to participate in the study will be
provided with a full verbal explanation of the trial and
the Patient Information Sheet. This will include detailed
information about the rationale, design and personal
implications of the study. After information is provided
to patients, they will have sufficient time to consider
participation before they are asked whether they would
be willing to take part in the trial. It is imperative that
written consent be obtained before any trial-specific pro-
cedures commence.
Randomization, concealment, and blinding
Participants fulfilling the entry criteria at screening will
be randomly assigned in a ratio of 1:1 to receive one of
the two treatment sequences (active treatment followed
by placebo, or vice versa). The randomization technique
is based on permutated balanced blocks with random
block length. The procedure considers stratification by
study site and by genetic vs. sporadic CA to ensure bal-
anced strata, maintaining allocation concealment. The
allocation sequence will be generated by an independent
person from the Institute of Medical Informatics, Biometry
and Epidemiology (IBE) of the University of Munich who
is not involved in assessing study outcomes. Neither the
investigators nor other trial staff (data analysts, statisti-
cians) or the patients will be informed about the treatment
sequences to which a patient is allocated, and neither
has access to the randomization list. Thus, random-
isation will be conducted without any influence of the
investigators or trial staff. The IBE will provide an
internet-based, password-protected randomization tool
(“Randoulette”: https://wwwapp.ibe.med.uni-muenchen.de/
randoulette), which chooses the treatment sequence for a
new patient who fulfills the eligibility criteria and has
signed the informed consent. Randoulette will register the
patient by his or her screening number, gender, year of
birth and strata before the allocated package number is
provided. The current trial is subject— and investigator-
blinded. Patients, clinicians, core laboratories, and trial staff
Table 1 Inclusion and exclusion criteria for patient selection
Inclusion criteria Exclusion criteria
• Clinically confirmed CA with a SARA total score≥ 3 (range 0-40)
(CA (hereditary or non-hereditary, non-acquired)
• Patient did not receive any of the following prohibited medication
within 4 weeks prior to randomization:
o Aminopyridines
o Acetyl-DL-leucine
o Riluzole
o Gabapentin
o Varenicline
o Chlorzoxazone
• The ability to follow study instructions and likely to attend and
complete all required visits
• Written informed consent of the subject prior to any
study-specific intervention
• Age ≥ 18 years
• Subject is not able to give consent
• Onset of ataxia in association with stroke, encephalitis, sepsis, hyperthermia
or heat stroke
• Toxic causes for ataxia of cerebellar type
• Rapid progression of ataxia (development of severe ataxia in less than
12 weeks)
• Subject suffers from any of the following:
o chronic diarrhea
o unexplained visual loss
o malignancies
o insulin-dependent diabetes mellitus
• Ataxia due to multiple sclerosis, ischemia, hemorrhage or tumor of the
posterior fossa as confirmed by imaging
• Ataxia due to clinically likely multisystem atrophy type C (MSA-C)
• Diagnosis of clinically likely Friedreich’s ataxia
• Known history of hypersensitivity to the investigational drug or derivatives
• Liver failure defined as AST/ALT > 300 U/l
• Simultaneous participation in another clinical trial or participation in any
clinical trial involving administration of an investigational medical product
within 30 days prior to the beginning of the clinical trial
• Subjects with a physical or psychiatric condition which, in the opinion of the
investigator, may put the subject at risk, may confound the trial results, or
may interfere with the subject’s participation in this clinical trial
• Known or persistent abuse of medication, drugs or alcohol
• Females of childbearing potential, who are not using and not willing to use
medically reliable methods of contraception for the entire study duration as
listed in the patient informed consent form
• Current or planned pregnancy or nursing women
• Patient has received any of the following prohibited medication within 4
weeks prior to randomization
o Aminopyridines (including sustained-release form)
o Acetyl-DL-leucine
o Riluzole
o Gabapentin
o Varenicline
o Chlorzoxazone
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(including data analysts and statisticians) will be unaware
of the treatment that the participant will take during both
double blind treatment periods.
Un-blinding will occur in the event of a clinical emer-
gency in which the knowledge of the medication being
taken is essential for the participant’s clinical manage-
ment. The investigator is supplied with an opaque sealed
envelope for each participant that contains the corre-
sponding treatment sequence for unblinding. Alterna-
tively, the randomization code can be broken using
Randoulette.
Trial procedures and interventions
Each treatment sequence consists of a first treatment
period of 6 weeks (42 days), followed by a 4-week
(28 days) wash-out period, and a second treatment
period of 6 weeks (42 days). Finally, a post-treatment
follow-up is scheduled 4 weeks (28 days) after the end of
the second treatment period (see fig. 1). The 4-week
wash-out period between consecutive treatments is as-
sumed to be long enough to allow the effects of a treat-
ment to wear off and prevent carry over from one
treatment period to the next.
Patients will be screened and assessed for eligibility at
visit 1. If within 4 weeks prior to visit 1 a patient has re-
ceived any of the prohibited medications defined in the
eligibility criteria, irrespective of the preceding treatment
duration, a wash-out period of 4 weeks (screening
period), prior to enrolment is required. Patients eligible
for entry in the study will be randomized and assigned
to one of the two sequence groups at visit 2. Visits 1 and
2 coincide if patients are not on prohibited medication
4 weeks prior to recruitment. At baseline, data on demo-
graphic and clinical characteristics including neuro-
logical assessment, ataxia rating scales, information
about preceding physio– and speech therapy as well as
patient questionnaires will be obtained. Figure 1 displays
the crossover intervention scheme. Table 2 lists the
schedule of enrolment and assessments together with
pre-planned time points for clinic visits. Including the
eligibility screening visit 1 and the post-treatment
follow-up visit 8, a total of eight study visits (three in
each treatment period) are scheduled.
Investigative drug and placebo
In the experimental treatment period, patients will re-
ceive tablets of acetyl-DL-leucine 500 mg (Tanganil®,
manufactured by Pierre Fabre, Castres, France) (other
ingredients: wheat starch, pregelatinized corn starch,
calcium carbonate, and magnesium stearate as filling
material). Tablets containing the active ingredient will be
refilled from original packaging into blisters under sterile
conditions and relabeled by the pharmacy of the univer-
sity hospital of Heidelberg. An identically appearing tab-
let filled with wheat starch, pregelatinized corn starch,
calcium carbonate, and magnesium stearate but not
containing any active ingredient will be administered
as placebo. Study medication blisters will be packed
in boxes and study kits will be delivered to the par-
ticipating centers.
Study medication will be delivered to the patient at
the beginning of a 6-week treatment period (visits 2 and
5, respectively). Patients are instructed to apply a 2-week
up-titration scheme and will be provided with written
Fig. 1 ALCAT trial: crossover intervention scheme. Screening (visit 1) and visit 2 can take place on the same date, if patients are not on prohibited
medication within 4 weeks prior to enrolment. If patients have received any of the prohibited medications 4 weeks prior to enrolment, a wash-
out period of 4 weeks prior to visit 2 (randomization) is required to rule out a carryover effect
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information. The up-titration scheme is as follows: in
the first week an initial dosage of 1.5 g per day
(500 mg t.i.d.), followed by 3 g per day (500 mg 2 tablets
t.i.d.) in the second week. After that (and another study
visit), the full dosage of 5 g per day (500 mg 3–3–4) will
be administered for another 4 weeks. If adverse events
(AEs) are noted, patients are permitted to down-titrate
to a minimum dosage of 1.5 g per day (in the maintain-
ing phase from week 3 to 6) within the current treat-
ment period, which is then considered to be their
maximal dose. The patients are instructed that the study
medication has to be taken at least 30 min before and at
least 2 h after a meal. Treatment adherence will be
assessed by counting tablets at the end of the treatment
period, and by recording the number of skipped intakes.
Study objectives and outcomes
The primary objective of the ALCAT trial is to demon-
strate that acetyl-DL-leucine is effective at improving
motor function measured by the SARA total score. The
primary efficacy endpoint is the absolute change in the
SARA total score from period-level baseline to the end of
the 6-week treatment period, i.e. the difference between
post-treatment values at the end of each treatment period
and the corresponding period-level baseline values:
Delta SARAtotalð Þ ¼ SARAtotal post‐treatmentð Þ
– SARAtotal period baselineð Þ
We presume a minimum clinically relevant difference
in the SARA total score of 1.5 points. The secondary ob-
jectives are to determine whether Acetyl-DL-Leucine is
effective at:
a) improving motor function measured by the
Spinocerebellar Ataxia Functional Index (SCAFI)
and SARA subscore items
b) improving QoL, as well as the common
comorbidities depression and fatigue.
The secondary efficacy outcome measures will be ab-
solute changes in the subscores of SARA as well as the
Table 2 Schedule of enrolment, interventions, and assessments
Enrollment Treatment period 1 Treatment period 2 Close-out
Before Eligibility
Screening
Visit 1c
Visit 2
(Baseline)
Visit 3
2 weeks
after V2
Visit 4
6 weeks
after V2
Wash-out
4 weeks
Visit 5 Visit 6
2 weeks
after V5
Visit 7
6 weeks
after V5
Follow-up Visit 8
4 weeks after V7
Timeline (days) 0/-28 0 14 42 70 70 84 112 140
Informed consenta X
Inclusion/exclusion criteria X
Medical history, including
demographics & medications
X
Documentation of physiotherapy/
speech therapy
X Xb X X X X X X
Neurological examination X
Blood tests Xd Xd Xd Xd
Randomization X
Dispensing of trial drug X X
Return of trial drug X X
Compliance check X X X X
Patient questionnaires
(EQ-5D-5 L, BDI-II, FSS)
X X X X X X X
Ataxia rating scale: SARA X Xb X X X X X X
Ataxia rating scale: SCAFI X X X X X X X
Documentation of (S)AEs X Xb X X X X X X
Documentation of concomitant
medication (drug history)
X X X X X X X
A delay of -3 and +5 days is acceptable for visits 2 and 5, for all other visits a delay of ± 5 days is acceptable
aprior to first study-specific intervention and allocation
bIf visit 1 and visit 2 take place at the same time, the ataxia rating scale (SARA), documentation of physiotherapy/speech therapy and documentation of (S)AE are
assessed only once
cIf patients are on medication due to cerebellar symptoms at visit 1, a 4-week wash-out (screening period) prior to randomization at visit 2 is required (adherence
will again be checked before randomization at V2). Otherwise, visit 1 and visit 2 coincide
dincl. negative pregnancy test for women of childbearing potential
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SCAFI total score and subscores of SCAFI (8 MW
testing gait, 9HPT testing limb ataxia and the PATA rate
task for speech). Furthermore, patient-reported out-
comes using the EuroQoL 5 dimensions and 5 level
version (EQ-5D-5 L), Beck’s Depression Inventory (BDI-
II) as well as the Fatigue Severity Scale (FSS) will be
recorded.
For all these scores, the treatment effect will be
assessed at the end of each treatment period and at the
post-treatment follow-up visit.
During the whole study period any AE (any untoward
medical occurrence, including an abnormal laboratory
finding, regardless of its causal relation to the study
treatment) will be recorded.
Ataxia rating scales
The clinical severity of ataxia will be assessed by two dif-
ferent clinical ataxia rating scales — namely SARA [24]
and SCAFI [25, 26]. The scores will be assessed by the
investigators. Both scales assess ataxia and dysarthria,
and are widely used in clinical practice [26] and clinical
trials covering the whole range of impaired motor func-
tion in ataxic patients. The scales are measured at each
clinic visit.
The SARA total score serves as a key inclusion criter-
ion measuring the severity of ataxia prior to enrollment.
The SARA total score has eight categories reflecting
neurologic manifestations of CA. Each category repre-
sents a crucialmovement feature in CA rated by an
examiner (gait, stance, sitting, speech disturbance, finger
chase, nose-finger test, fast alternating hand movements,
heel-shin slide) resulting in a score ranging from 0 (no
ataxia) to 40 points (most severe ataxia). It is a reliable
and valid clinical scale with a high internal consistency
that measures the severity of ataxia and increases with
disease stage [25, 27, 28].
The SCAFI includes the 8 MW testing gait, the 9HPT
testing limb ataxia and the PATA rate task for speech
and therefore represents vital movement features. In
contrast to the SARA, the SCAFI uses a timed approach
rated by an examiner. After the assessment, raw scores
are transformed into reciprocals and converted into sub-
test Z-scores. The resulting SCAFI is defined as the
arithmetic mean of all three Z-scores.
Patient questionnaires for quality of life, depression and
fatigue
A self-administered questionnaire to evaluate QoL,
namely the EQ-5D-5 L [29] (multiple choice question-
naire and a visual analogue scale) will be used. The EQ-
5D-5 L is a standardized measure of health status that
provides a simple, generic measure of health for clinical
and economic appraisal and consists of 2 parts — the
EQ-5D descriptive system and the EQ visual analogue
scale (EQ-VAS). The EQ-5D-5 L descriptive system
comprises the following 5 dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/de-
pression. Each dimension has 5 levels: no problems,
slight problems, moderate problems, severe problems,
and extreme problems.
As depression and fatigue are known common comor-
bidities in patients with CA, trial participants are
instructed to complete the BDI-II [30–32] and FSS [32]
questionnaires at each clinic visit. The BDI-II is a
multiple choice self-report inventory for measuring the
severity of depression and is composed of items related
to symptoms of depression such as hopelessness and ir-
ritability, emotions such as guilt or feelings of being
punished, as well as physical symptoms such as fatigue,
weight loss and lack of interest in sex. The FSS captures
the patient’s experience of mental or psychological
fatigue and how it interferes with performing certain
activities (exercise, work and family life). It is a self-
reporting scale of 9 items. The mean of all answered
items represents the fatigue severity.
Laboratory examinations
A routine blood sample will be taken to exclude liver or
kidney failure, and a pregnancy test for women of child-
bearing potential will be performed. A pregnancy test is not
required for postmenopausal (amenorrhea >12 months),
surgically sterilized or hysterectomized women. The follow-
ing laboratory parameters will be assessed (but not rou-
tinely documented in the CRF): sodium, potassium,
creatinine, serum bilirubin level, AST, ALT, urea, ALP,
TSH, hemoglobin, erythrocytes, hematocrit, thrombocytes,
leukocytes, pregnancy test for women of childbearing po-
tential. In a case of an AE, laboratory parameters will be
documented. The total amount of blood taken per subject
during the entire trial will be approximately 20 ml. Labora-
tory examinations are carried out at visit 1, visit 4, visit 5
and visit 7.
Concomitant drug and non-drug therapies
Trial participants should not begin physiotherapy or
speech therapy while they are enrolled in the trial. If
they are already under therapy, the amount of sessions
of physiotherapy and speech therapy (measured in hours
of therapy per week) will be documented in the patient’s
medical record and in the case report form (CRF) during
the trial and for 6 months prior to randomization. To
adhere to the protocol, the non-pharmacological con-
comitant therapy should be continued with the same in-
tensity while the patient is enrolled in the trial.
Guided by the eligibility criteria, the administration of
4-aminopyridine, Riluzole, Varenicline, Gabapentin or
Chlorzoxazone is not allowed during the trial because of
a possible beneficial effect in CA.
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Participation discontinuation and follow-up of
participants ‘off protocol’
If a participant withdraws from the study, the reason will
be documented. ‘Off protocol’ is defined as those study
participants who cease trial medications on clinical
grounds. Regardless of the decision to continue with
study medication, these participants will be asked to par-
ticipate in all scheduled follow-up appointments, as if
they were maintaining full participation, in order to pre-
vent further missing data. Those who are unwilling or
unable to do this will be asked to agree to a phone or
mail follow-up, and/or permission for study staff to con-
tinue ascertainment of outcomes.
Statistical planning and analyses
Power considerations and sample size calculation
The sample size was calculated on the basis of the pri-
mary hypothesis, using our own preliminary case series
data (13 patients [17]) and a similar placebo-controlled
trial (20 patients [7]) investigating the efficacy of vareni-
cline on the change in SARA total score in patients with
SCA 3. Hence, assuming a minimum clinically relevant
difference in the SARA total score of 1.5 points [25] to
be detected (i.e. the absolute change on acetyl-DL-
leucine is 1.5 score points better than the change on pla-
cebo) and a standard deviation of the individual SARA
change of 4.2, a sample size of 86 (85 is calculated but 2
sequences are needed) in total is will have 90% power to
detect a difference in means of 1.5, using a paired t-test
with a 0.05 two-sided significance level [Software used:
nQuery Advisor 7.0]. On the basis of our experience
with patient compliance in previous studies, we expect a
dropout rate of about 20%. Thus, a total of 108 patients
have to be enrolled. With a proportion of about 50–55%
recruited patients out of the number to be screened,
about 200 patients have to be assessed for eligibility.
There is no interim analysis planned for this study.
Statistical analyses for primary and secondary endpoints
Efficacy analyses are based on the intention to treat
(ITT) principle in that all participants randomized will
be analyzed according to the treatment sequences to
which they were allocated and irrespective of the extent
of intervention received. In this study, the term ‘full ana-
lysis set’ is used to describe the analysis set, which is as
complete as possible and as close as possible to the ITT
ideal of including all randomised participants (i.e, the
ITT population). All statistical tests are two-sided, and
the significance level alpha is set to 5%.
For the primary efficacy outcome change in SARA
total score (DeltaSARA), the null hypothesis will be
tested that there is no difference in mean change be-
tween placebo and acetyl-DL-leucine.
Absolute change, calculated as the difference between
the period-level baseline score and the score measured
at the 2-week and 6-week visits of the acetyl-DL-
leucine/placebo period, will be considered for a model-
based primary efficacy analysis. If not revised in the
statistical analysis plan (SAP), a linear mixed effects
model for DeltaSARA will be performed (fixed effects:
factor for treatment, visit, treatment-by-visit interaction,
and mean of both period-level baseline SARA total
scores as covariate; normally distributed patient-specific
random intercepts and slopes) in order to deal with re-
peated measurements within periods and measurements
not made at equivalent times in each subject due to un-
scheduled or missed clinic visits. This subject-specific
modelling approach allows individual change scores over
time to be calculated. To analyse the differences between
both interventions at the end of the 6-week treatment
period, 95% confidence intervals will be provided to
quantitatively describe treatment effects.
Sensitivity analyses will be performed on a per protocol
approach which takes into account treatment adherence
and compliance with the trial protocol. Additional efficacy
analyses adjusting for genetic vs. sporadic CA, gender, age,
or trial site, will be performed. In addition, the robustness
of the overall efficacy result will be investigated by ana-
lyses adjusting for the amount of physiotherapy the pa-
tient received when he or she was enrolled in the trial
(which should be comparable to the amount received be-
fore randomization), as considered appropriate during the
blinded data review and depending on the data quality.
Since this analysis will also be based on variables mea-
sured after randomization, the susceptibility for bias will
be given consideration and will be discussed.
In case of a statistically significant primary efficacy result,
confirmatory testing will be extended to the EQ-5D-5 L
(VAS and descriptive scale). SCAFI (total score and 3 sub-
scores), SARA subscale items, as well as patient-reported
outcomes BDI-II and FSS are not considered in the hier-
archical multiple testing procedures. Descriptive compari-
sons between treatment groups at the end of the 6-week
acetyl-DL-leucine/placebo period will be performed using
a two-sided Wilcoxon signed rank test, and additionally,
Hodges-Lehmann estimation of the location shift between
the two groups will be provided, as considered appropriate
based on the blinded data. The same non-parametrical
tests will be employed to estimate treatment differences at
the follow-up visit 8 (close-out visit). Further methodo-
logical details will be provided in the SAP.
Safety assessment
Outcome assessors will judge the severity (mild, moderate,
or severe), seriousness, and causality (definitely related,
probably related, possibly related, possibly not related, def-
initely not related to the intervention, or not assessable).
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All adverse events will be listed by trial site and patient
and displayed in summary tables. The incidence of adverse
events and their relationship to the study drug will be ana-
lyzed descriptively, guided by the Medical Dictionary for
Regulatory Activities (MedDRA) classification.
Data collection
Results from the trial assessments will be recorded in an
electronic CRF (e-CRF) via a validated open-source elec-
tronic data capture (EDC) system based on the OpenCli-
nica® Community Edition. At each clinical site, study
personnel will enter data directly into the EDC system.
Data will be transferred on a regular basis to the official
study database stored in SAS (Version 9.2 for Linux, SAS
Institute, Cary, NC) for quality checks and query manage-
ment. Statistical analyses will be performed using SAS, as
well as the software package R version 3.3.0 or higher [33].
Data safety and monitoring board (DSMB)
An independent DSMB has been established. The func-
tion of the DSMB is to monitor the course of the study
and if necessary to give a recommendation to the coord-
inating investigator and sponsor of the trial for discon-
tinuation, modification or continuation of the study.
Furthermore, the DSMB will periodically review the
safety data of Development Safety Update Reports.
Discussion
Because there is no approved causal or symptomatic
drug therapy yet, there is an urgent need for effective
and well-tolerated drug treatment. Based on different
case series in hereditary or non-hereditary non-acquired
CA of different etiologies [17, 19, 22] and its good safety
profile (since 1957 on the market in France for symp-
tomatic dizziness and vertigo treatment) the modified
amino-acid acetyl-DL-leucine is a good candidate.
In this multicenter, multinational, randomized, double-
blind, placebo-controlled, phase III trial, short-term treat-
ment efficacy and safety are evaluated with a 2-treatment
2-period crossover design comprised of 6-week treatment
periods. The primary inclusion criterion SARA total score
of at least 3 points ensures that patients are at least mod-
erately affected by the disease and allows CA patients with
a wide spectrum of clinical severity to be included. Except
for the blood tests, all examinations and assessments
applied are non-invasive and also performed in clinical
routine. If superiority of acetyl-DL-leucine compared to
placebo intervention can be established, this medication
could offer a complete new therapeutic approach for the
target population. Due to the high prevalence and the
participation of many centers in three European countries,
recruitment to reach the target sample size of 108 partici-
pants seems achievable within the planned time frame of
32 months. Due to the pragmatic nature of the trial
design, the primary question of interest relates to inter-
vention effectiveness, i.e. whether the intervention works
under real-life conditions. In particular, trial participants
are allowed to maintain physio- or speech therapy during
the trial provided that they have already started this ther-
apy before recruitment.
Of course, this trial has some limitations: first, so far
we do not know what the optimal dosage is. The dose of
5 g per day used in this trial is based on case series. Sec-
ond, we do not know what the optimal dosage interval
is. Third, since the plasma levels are not measured, we
cannot correlate them with the clinical effect and we
cannot exclude patients taking acetyl-DL-leucine in
addition to the study medication. Fourth, as we include
multiple types of CA (hereditary or non-hereditary non-
acquired) we will not know if the agent is more effective
with one CA than with another due to small numbers of
the different CA types. Last, but not least, the observa-
tional period is quite short, so we cannot evaluate the
effect of the drug on the long-term progression of the
disease compared to placebo intervention. This, how-
ever, could easily be done as soon as its efficacy and
safety in symptomatic treatment is demonstrated.
Trial status
At the time of manuscript submission, the study design
had been evaluated by independent international reviewers
and has been approved by the responsible ethics commit-
tee of the University of Munich and the ethics committee
in Austria as well as the authorities in Germany (BfArM)
and Austria (AGES). The study is being prepared for sub-
mission in the Netherlands. The first study participant was
randomized on January 25, 2016 with the opening of the
trial site of the coordinating investigator. As of October,
1st, we have included a total of 92 patients.
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